68 results about "Immunological diseases" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immunological disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

The present application provides anti-IL-13 antibodies and antigen binding fragments thereof. Such antibodies and antigen binding fragments thereof may be used in methods for the treatment and / or prevention of an immunological disease or disorder.

The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-lymphocytes, and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.

The present invention relates to compounds having cyclin-dependent kinase (CDK)-inhibitory functions and / or pharmaceutically acceptable salts thereof, the use of these compounds as pharmaceutically active agents, especially for the prophylaxis and / or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing such compounds.

Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided.

A compound represented by general formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, and a use thereof in treating diseases such as tumors, immunological diseases, and inflammatory diseases, as well as a pharmaceutical preparation and a pharmaceutical composition of the compound, and a use thereof.

Provided are immunomodulatory proteins containing an engineered variant CD80 extracellular domain that exhibits improved PD-L1 binding. The immunomodulatory proteins include variant CD80 domains with amino acid substitutions in the IgV domain. Among the provided immunomodulatory proteins are variant CD80-Fc fusion proteins. Also provided are cell therapies, such as T cell therapies, engineered with secretable or transmembrane immunomodulatory proteins containing the variant CD80 disclosed herein. In some aspects, the provided immunomodulatory proteins are capable of antagonizing PD-1 / PD-L1 in addition to providing CD28 costimulation in a PD-L1-dependent fashion. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders, or conditions, such as cancer. Also provided are compositions and methods for making and using such immunomodulatory proteins as well as compositions and methods for making and using such cell therapies.

To provide methods for preparing novel immunoregulatory macrophage cells which are useful in the treatment of different immunological and non-immunological diseases and conditions; resulting macrophage cells; and pharmaceutical compositions comprising macrophage cells.SOLUTION: A method for preparing an immunoregulatory macrophage cell is provided, the method comprising: (a) isolating CD14 positive monocytes from a blood sample of a subject; (b) culturing the monocytes in a gas-permeable bag in a culture medium containing (i) M-CSF and / or GM-CSF, and (ii) a CD16 ligand; (c) contacting the cells with IFN-γ; and (d) obtaining the immunoregulatory macrophage cell from the culture medium.SELECTED DRAWING: Figure 10

The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing system, small molecules, vectors or host cells, that comprises and / or modulate expression or activity of immune regulation-associated proteins. The disclosure also provides, in various embodiments, methods of treating aging, senescence, fibrosis, a metabolic disease, cardiovascular disease, an endocrine-associated disorder, a genetic disease, cancer, an infection, an immunological disease, an indication treated with hormone, growth factor and / or protein replacement, or a combination thereof using an agent that comprises and / or modulates expression or activity of an immune regulation-associated protein and methods of identifying said agent.

The present invention provides a novel multi-strain probiotic formulation and relates to the use of the multi-strain formulation in therapy, in particular for the treatment or prevention of immunological or allergic diseases / disorders, such as allergic rhinitis or allergic conjunctivitis. In addition, the present invention also provides a novel therapeutic regimen that is easy to follow using the probiotic formulations provided herein.

Provided is a novel camptothecin derivative or a conjugate thereof, and a preparation method therefor and an application thereof in medicine. Specifically, provided is a compound represented by general formula (A) or a ligand-drug conjugate thereof, a preparation method therefor, and an application of the ligand-drug conjugate and a pharmaceutical composition thereof in the preparation of a drug for the treatment of cancer or immunological diseases.

Defined herein are immunomodulating Formula (1) compounds, wherein R, R0, R1, R2and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating or preventing an inflammatory and / or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof; or use of said Formula (1) compound to prepare a medicament for treating or preventing an inflammatory and / or immunological disease or disorder in an animal.

Novel Halogenated Benzylidine derivatives are provided which exhibit activity for the treatment of immunological diseases and inflammation

The invention relates to the field of medicinal chemistry and medicine, and discloses pentacyclic triterpene derivatives and application thereof in prevention and / or treatment of immune diseases. The pentacyclic triterpene derivative disclosed by the invention has a structure as shown in a formula (I) and has an excellent immunoregulation effect on Tc1, Tc17 and Th17 cells, and the invention also provides application of the compound in preparation of medicines for preventing and / or treating immune diseases.

The invention relates to the technical field of molecular immunology and biology, in particular to a sicca syndrome model mouse B cell immune repertoire sequencing and subpopulation analysis method. The method comprises the following steps: S1, sample preparation: preparing a single-cell suspension from a target autoimmune disease animal model and a preset tissue of a control animal, and carrying out B cell enrichment treatment on the single-cell suspension to obtain a B cell sample; s2, multi-dimensional data parallel analysis: analyzing the B cell sample, and performing parallel construction of the multi-dimensional data; and S3, integrated correlation analysis: carrying out correlation analysis on the immune group library data, the cell subset data and the signal channel data obtained in the step S2 to establish a correlation relationship among specific B cell cloning characteristics, specific B cell subset changes and specific signal channel activity, and carrying out multilevel analysis and generating a B cell immune response mechanism of the autoimmune disease. The efficiency and accuracy of disease mechanism research and drug action mechanism evaluation are remarkably improved.

Disclosed herein are engineered Treg cells comprising a nucleic acid comprising a thermally-inducible promoter operably linked to a polynucleotide encoding an immunostimulatory agent gene. Also included are compositions thereof and methods and kits suitable for use in treating autoimmune diseases. In some embodiments, the method comprises administering a composition comprising engineered T cells. The engineered T cells can comprise thermally actuatable genetic circuits encoding immunostimulatory agents.

The invention provides methods for assessing immune system function and status based on cellular analysis. Methods of the present invention involve obtaining mass properties of immune cells collected in a tissue or body fluid sample from a subject. Such mass properties may include the mass of one or more immune cells and / or changes in mass of such immune cells over a period of time. Such data is then used for determining a status of the subject's immune response, and subsequent diagnosis and treatment of an infection or immunological disease or dysfunction.

This invention provides a device for applying ointments for rheumatic and immunological diseases, comprising a box body with an ointment chamber at the top and a buffer chamber inside the box body, the buffer chamber having a flat opening; a control rod rotatably connected to the inner cavity of the buffer chamber, a buffer plate being provided on one side of the control rod, and a first spring connecting the buffer plate and the buffer chamber; a conveyor plate rotatably mounted inside a cylindrical chamber, the conveyor plate having multiple transfer grooves evenly distributed around its circumference; a first tube being provided on the top side of the cylindrical chamber and a second tube being provided on the bottom side; a drive mechanism capable of driving the conveyor plate to rotate. The ointment continuously flowing into the buffer chamber pushes the buffer plate towards the bottom of the buffer chamber, and the first spring also provides an elastic force that pushes the buffer plate upwards. Under the mutual pushing action of the ointment and the buffer plate, the ointment is compressed, reducing gaps and air bubbles, and is discharged from the flat opening, resulting in a uniform and dense ointment without gaps, eliminating the need for secondary coating and repair, and reducing drug waste while ensuring drug absorption.

The present invention relates to novel immunoregulatory macrophage cells which are useful in the treatment of different immunological and non-immunological diseases and conditions. The cells are characterized by a specific marker and activity pattern which distinguishes them from other cells. The invention also provides a process for preparing the immunoregulatory macrophage cells from blood monocytes. In a still further aspect, the invention relates to a pharmaceutical composition comprising the immunoregulatory macrophage cells of the invention or a sub-cellular fraction thereof. A process for preparing a sub-cellular fraction of an immunoregulatory macrophage cell of the invention is also provided.

A pharmaceutical use of a pharmaceutical composition containing platinum drugs or platinum drug co-crystals as main active substances in preventing or treating immunological diseases such as rheumatoid arthritis, and other diseases. The platinum drugs mainly refer to oxaliplatin, and the platinum drug co-crystals mainly refer to carboplatin co-crystals or oxaliplatin co-crystals. Further disclosed is a method using platinum drugs or platinum drug co-crystals, either alone or in combination with at least one additional therapeutic agent or adjuvant therapy agent.

The application relates to the field of medical devices, in particular to a joint protection device suitable for children with rheumatic and immunological diseases, which comprises a joint protection sleeve, a plurality of first sliding grooves and a plurality of connecting rods are arranged on the two sides of the joint protection sleeve, the first sliding grooves and the connecting rods are in one-to-one correspondence, when the joint protection sleeve wraps the joint, the connecting rods are inserted into the first sliding grooves, and the connecting rods and the first sliding grooves are in sliding cooperation; the adjusting holes and the anti-occlusion mechanisms are communicated in the first sliding grooves, the opening and closing mechanisms are communicated on the communication paths of the adjusting holes and the first sliding grooves, and the opening and closing mechanisms are used for controlling the on-off of the adjusting holes and the first sliding grooves; the anti-occlusion mechanisms are used for connecting the first sliding grooves with the outside based on the negative pressure size in the first sliding grooves. The application can realize dynamic adaptation and intelligent protection, and reduce the occlusion risk caused by rigid fixation of the device.

The invention provides a polypeptide and application thereof in preparation of an immunomodulatory product. It is found that the polypeptide with the amino acid sequence shown as SEQ ID NO: 1 can significantly improve the secretion amount of macrophage inflammatory factors and the ROS generation amount, enhance immunity, significantly reduce the influence of LPS on macrophage NO release and inflammatory factor secretion and repair immune imbalance caused by excessive inflammation, and it is indicated that the polypeptide has excellent immunoregulation activity and can be used for preparing immunomodulatory drugs for treating the macrophage NO release and inflammatory factor secretion. In other words, the polypeptide is suitable for preparing products for enhancing immunity, immunoregulation products and drugs for preventing and / or treating immune diseases.

The present application provides anti-IL-13 antibodies and antigen binding fragments thereof. Such antibodies and antigen binding fragments thereof may be used in methods for the treatment and / or prevention of an immunological disease or disorder.

To provide methods for preparing compositions enriched in T regulatory cells (Tregs) and methods for treating immunological diseases using the compositions, and to provide methods for preparing compositions enriched in lymphocytes and depleted of Tregs and use of the compositions in treating proliferative diseases.SOLUTION: A method for preparing a composition enriched in CD4+CD25hi T regulatory cells (Tregs) is provided, comprising contacting in vitro a population of human cells including T lymphocytes obtained from a patient-derived human blood or bone marrow sample with a tumor necrotic factor receptor 2 (TNFR2) agonist or an NF-κB activator, thereby preparing the composition in which the Tregs are enriched, wherein the Tregs constitute at least 60% of the cells in the composition.SELECTED DRAWING: None

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract 20 26 21 41 08 10 A ug 2 02 6 A b s t r a c t 2 0 2 6 2 1 4 1 0 8 1 0 A u g 2 0 2 6

The disclosure provides, in various embodiments, compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors or host cells, that comprise and / or modulate expression or activity of immune regulation-associated proteins, such as cytokines. The disclosure also provides, in various embodiments, methods of treating inflammation, aging, senescence, fibrosis, autoimmunity, cancer, an infection, and / or an immunological disease using an agent that comprises and / or modulates expression or activity of an immune regulation-associated protein, and methods of identifying said agent.

The present invention introduces a novel immunotherapeutic approach utilizing dual-targeting cancer cell therapy. This therapy involves dual -targeting constructs that co-express either chimeric antigen receptors (CARs) alone or a CAR with a bispecific T-cell engagers (BiTEs) to target two distinct antigens. This innovative design minimizes antigen escape and enhances cytotoxic efficacy by harnessing the advantages of both CAR-T cells and BiTEs. Additionally, the invention discloses the use of bidirectional or in-line promoters to co-regulate the expression of dual CARs or co-expression of a CAR and a BiTE. It also provides polynucleotide and amino acid sequences for these dual -targeting CAR constructs, with or without BiTEs, for the treatment of B-cell malignancies, autoimmune disorders, and other B cell-related diseases.

The invention relates to the technical field of joint puncture, in particular to an ultrasonic-guided joint puncture device for rheumatism immune disease diagnosis, which comprises a supporting seat, an electric sliding rail is mounted at the lower end of the supporting seat, a first sliding seat slides on the upper surface of the electric sliding rail, and a second sliding seat slides at the upper end of the first sliding seat. The upper surface of the second sliding seat is slidably connected with a positioning ring, two sets of guide buckles are installed at the lower end of the second sliding seat, and sliding rods are slidably arranged in the two sets of guide buckles. The puncture position and the diagnosis position are kept consistent, diagnosis errors or tissue damage risks caused by puncture deviation are reduced, and meanwhile, through scale marks on the outer sides of the two sets of sliding rods, medical staff can visually observe the puncture depth of the puncture needle through the displacement of the two sets of sliding rods in the limiting ring.

To provide methods and therapeutic compositions for modulating immune response in the treatment of cancer and immunological diseases.SOLUTION: Immunomodulatory proteins comprising ICOS ligand (ICOSL) variants and nucleic acids encoding the proteins are provided herein. The immunomodulatory proteins provide therapeutic usefulness for various immunological and oncological conditions. Compositions and methods for producing and using the proteins are provided.SELECTED DRAWING: Figure 1A